Johnson & Johnson vs Dr Reddys Laboratories
JNJ and RDY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JNJ and RDY compare
Johnson & Johnson grew revenue faster over the last twelve months (8.1% versus 3.2% for Dr Reddys Laboratories).
Johnson & Johnson keeps more of each dollar of sales as profit, with a net margin of 21.5% compared with 12.8% at Dr Reddys Laboratories.
Johnson & Johnson pays a dividend yielding 1.9%; Dr Reddys Laboratories does not pay one.
Johnson & Johnson scores higher on the StockData Score (12 against 7 for Dr Reddys Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JNJ | RDY |
|---|---|---|
| Size and price | ||
| Market cap | $658B | – |
| Share price | $273.20 | $14.17 |
| Change, 1 year | 46.4% | 5.7% |
| Change, 5 years | 67.2% | 11.8% |
| Beta (5Y) | 0.20 | 0.37 |
| Employees | 138K | – |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 2 |
| Health score | 3 | 4 (better) |
| Dividend score | 2 (better) | 0 |
| Valuation | ||
| P/E | 31.7× | – |
| P/S | 6.7× | – |
| P/B | 7.7× | – |
| EV/EBITDA | 20.2× | – |
| P/FCF | 29.6× | – |
| PEG | 1.77 | – |
| FCF yield | 3.4% | – |
| Fair value | $190.51 | – |
| Margin of safety | −43.4% | – |
| Growth | ||
| Revenue growth (TTM) | 8.1% (better) | 3.2% |
| Revenue growth, 5Y average | 2.7% | 12.1% (better) |
| Net income growth (TTM) | −7.2% (better) | −24.2% |
| EPS growth (TTM) | −7.8% (better) | −24.1% |
| EPS growth, 5Y average | 14.9% | 19.9% (better) |
| Profitability | ||
| Gross margin | 67.9% (better) | 52.8% |
| Operating margin | – | 15.0% |
| Net margin | 21.5% (better) | 12.8% |
| FCF margin | 22.7% (better) | 10.0% |
| Return on equity | 25.7% (better) | 12.1% |
| Return on invested capital | – | 9.7% |
| Financial health | ||
| Debt / equity | 0.58 | 0.21 (better) |
| Net debt / EBITDA | 0.83 (better) | 0.87 |
| Interest coverage | – | 13.5× |
| Current ratio | 1.09 | 1.80 (better) |
| Altman Z-score | 5.11 | – |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | – |
| Payout ratio | – | 15.5% |
| Years of dividend growth | 16 (better) | 0 |
| Dividend growth, 5Y average | 5.2% | 9.9% (better) |
| Buyback yield | 1.2% | – |
| Shareholder yield | 3.2% | – |
| Ownership | ||
| Held by institutions | 74.7% | 15.1% |
| Held by insiders | 0.04% | 13.6% |
| Insider net buying, 12 months | −$150M | – |
| Superinvestors holding | 6 | – |
| Short interest, % of float | 0.92% | – |
Go deeper
- JNJ stock overview
- JNJ income statement
- JNJ valuation and score
- RDY stock overview
- RDY income statement
- RDY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.